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Abstract

PCBPl or poly (C) binding protein is a multifunctional protein, which belongs to the K
homology domain superfamily. Its multiple functions include mRNA stabilization,
translational regulation and transcriptional regulation, which have been found to affect
the expression of the mu-opioid receptor gene. PCBPl's multiple functions may likely
correlate to its various protein-protein interactions. We therefore examined its interacting
protein(s) using a two-hybrid system by screening a cDNA library. After more than 1
million clones were screened, a candidate interacting protein was identified as ysynuclein. The plasmid of this cDNA clone was purified and the interaction between
PCBPl and y-synuclein was further confirmed using in viva validation with the bacteria
system as well as using GST-pull down assay.

To further examine if this physical interaction can take place in a mammalian cell system,
several cell lines, including NMB (neuroblastoma), H292 (lung), HCTl16 (colorectal),
HT29 (colorectal), T47D (breast), and Mcf-7 (breast), were used. Western blot analysis
showed that these human cancer cell lines endogenously expressed PCBP1 and ysynuclein. The physical interaction of these two proteins was examined using cell Iysates
from these cell limes by co-Immunoprecipitation(co-IP) and subsequentially via Western
blot analysis. Results suggested a physical interaction between endogenous PCBPl and
y-synuclein. To further investigate if these cell lines expressed the identical 7-synuclein,

vii

RT-PCR was performed using RNA h m these cell l i e s with a y-synuclein specific
primer set. The PCR products were then subjected to DNA sequencing analysis.

The obtained DNA sequences were then compared with the published cDNA sequence in
GenBank. This comparison showed a consistent missense mutation at the C-terminus of
y-synuclein. This mutation created a valine (non-polar) residue in the cells, whereas and
a glutamic acid (acidic) residue in the database. A SNP database search was then
performed to determine if this missense mutation was a SNP (single nucleotide
polymorphism). A total of 53 SNPs were found for y-synuclein and one of them matched
the mutation found.

Since it is already known that PCBPl participates in the regulation of the mu-opioid
receptor gene expression, and based on this study that PCBPl can physically interact with
y-synuclein, the effect of this protein-protein interaction on MOR promoter was further
investigated using a luciferase reporter gene assay with the mammalian expression
plasmid containing each form of y-synuclein. Our preliminary results suggested that ysynuclein may be able to modulate MOR promoter activity, which will need to be f i d e r
confirmed. In conclusion, PCBPl and y-synuclein physically interact in the mammalian
system and this interaction may modulate PCBPl 's functional role.

viii

Introduction
PCBPl belong to K Homology superfamily
The K homology superfamily contains 3 KH (K homology) domains, which are nucleic
acid binding domains. They contain two K H domains near the N-terminus and a third
one near the C-terminus. The greatest sequential variance among the family lies in the
domain between the second M domain and the third KH domain. This variable domain
contains a NLS (nuclear localization signal), which gives this protein its ability to be
shuttled between the nucleus and the cytoplasm (Berry et al., 2006). This superfamily
contains two subcategories, the hnRNPs and the poly (C) binding proteins. PCBPl is a
member of the K homology domain superfamily, and is a protein approximately 38kDa in
size. It is also known as aCPl and hnRNP El. It is an ssDNA and RNA binding protein
which binds to poly cytosine residues. PCBPl displays various physiological roles,
including transcriptional regulation, translational regulation, and mRNA stabilization. It
can form protein complexes and work in conjunction with other proteins to carry out
various functions (Wang et al., 1999 and Rivera-Gina et al., 2006).

mRNA Stabilization
Binding of PCBPl protein can cause mRNA stabilization of many genes. Alpha-globin
mRNA is an example. PCBPl, PCBP2 and PABP (ply A biding protein) form an
alpha complex which binds to a sequence in the 3'UTR of alpha-globin mRNA. The
binding of this ribonucleoprotein complex prevents mRNA decay and prevents
deadenylation (Wang et al., 1999). Another example is that PCBPl along with hnRNP

A1 and hnRNP K b i d to a sequence at the 3' UTR of collagen mRNA, and this binding
stabilizes its mRNA and acts as a positive effector of synthesis (Thiele et al., 2004). A
similar effect is also seen in rain and gastrin genes (Lee et al., 2007 and Adam et al.,
2003). This increase in stability of mRNA and upregulation of protein synthesis caused
by PCBPl can also be seen for erythropoietin and tyrosine hydroxylase, but in a hypoxia
dependent condition by binding to the 3' UTR of their mRNA and regulating stability

(Zhu et al., 2002).

Transcriptional Regulption

Another function of PCBPl is that it can serve as a transcriptional regulator. This
function has been reported in two genes, eIF4E (eukaryotic translation initiation factor 4E)
and MOR (mu-opioid receptor). PCBPl binds to a specific sequence in the promoter
region of eIF4E which contains eIF4E basal element (4EBE) and increases transcription
(Meng et al., 2007). PCBPl binds to a specific ssDNA sequence in the proximal
promoter of mouse MOR gene and increases gene expression (KOet al., 2005).

Translational Regulation

PCBPl has also been reported as both a positive and negative translational regulator.
The positive translational regulation has been reported in the c-myc gene. The protooncogene c-myc contains an internal ribosome entry segment (IRES) at its S'UTR.
PCBPl, PCBP2, and hnRNP K bind to c-myc's IRES mRNA and this binding leads to
IRES mediated translation (Evans et al., 2003). Negative translational regulation has

been shown in the 15-lipoxygenase (LOX) gene. PCBPl along with PCBP2 and hnRNP

K form a complex and bind to the differential control element @ICE). The differential
control element is a CU rich repeated motif at the 3'UTR. The binding of this protein
complex prevents the 60s and 40s ribosome subunits from joining and forming the 80s
ribosome at AUG sequence. Without the joining of the subunits, translation cannot occur
(Ostarek et al., 1997). A similar effect is also reported in the A2 response element
(MRE), in which PCBPl and hnRNPA2 together bind to A2RE. With this binding, the
translation of A2RE RNA is prevented (Kosturko et al., 2006).

Other functions
PCBPl has also been found to affect the cytoskeletal composition of neurons. PCBPl,
PCBP2, and hnRNP K bind to the low, middle and high molecular mass neurofilament
subunit proteins. These subunits will then co-polymerize and form neurofilaments
(Thyagarajan et al, 2008). PCBPl has also been found to act as a chaperone in the
delivery of iron to femtin, an iron storage protein (Shi et al., 2008).

To further understand PCBPl's different functional roles, our laboratory investigated this
aspect by examining the protein-protein interactions using the two-hybrid system. This
system employed two vectors, a bait protein containing vector and the other vector
containing a cDNA library for screening candidate clone(s) of PCBP1 interacting protein.
PCBPl was used as the bait protein to screen its interacting protein(s) from a human
brain cDNA library. Over 1 million clones were screened, and y-synuclein was found to

be a candidate interacting protein. In viw validation was performed using the purified

plasmids via co-transformation. The confirmation of in vitro physical interaction was

also obtained using the GST-pull down technique (Lab unpublished data).

Synuelein Family and y-synuclein
The synuclein family contains a, $, and y synuclein. The synuclein family has high
amino acid sequence homology. Sequence comparisons show that a to $ has 62%
identity and 79% homology, a to y has 50% identity and 74% homology, and j3 to 7 has
47% identity and 66% homology. The highest divergence of amino acid sequence within

the synuclein family is found in the C-terminus (Sung et al., 2006). These proteins have
been shown to possess the ability to aggregate, and each member possesses different
propensities for aggregation. The a-synuclein has the greatest propensity, and 7 closely
resembles it in its h e state residual secondary structure. The j3-synuclein possesses the
least propensity for aggregation and it has been reported to protect a from aggregation in
vitro (Sung et al., 2007). At the current stage, the functions of these three proteins have
not been well understood.

The y-synuclein is also known as breast cancer specific gene l(BCSG1) and persyn, and
is a small intracellular protein about 13kDa in size (Buchman et al., 1998). It locates at
chromosome 10q23, and contains 5 exons coding for 127 amino acids (Lavedan et al.,
1998). It was originally found in the nervous system and considered to be a neural
protein (Malatynska et al., 2006). The y-synuclein has also been found to be over-

expressed in many malignancies and considered a bio~narker.It is related to
newodegenerative disorders including, Parkinson's disease, Alzheimer's disease,
Amyotrophic lateral sclerosis, Lewy body disease, and vascular dementia (MukaetovaLadinska and Lincoln et al., 1999). In addition, it has been reported recently highly
expressing in Retinal Ganglion Cells (RGCs) (Swgucheya et al., 2008).

Presence of 7-synuclein in Nervous System

The y-synuclein was initially found in nervous system tissue and is therefore considered
to be a neuronal protein (Zhao et al., 2006). The mRNA levels of synuclein-a, fl, and y
were quantified in different brain regions at different ages of mice. The hippocampus,
stria-,

cortex, and cerebellum were the regions used. The rank order of mRNA for y-

synuclein was hippocampus=striatum>cortex~erebellum.The rank order was different
for both synuclein a and fl. The levels varied in each region depending on mouse age.
For example, y-synuclein levels increased significantly only in the cerebral cortex from 5
d to 1 mo of age, but levels in the cerebellum were very high at 5 d and significantly
reduced at 1 mo. The different patterns and dynamics of mRNA levels of this family of
proteins as the mice aged suggests that they may play a role in development and aging
(Malatynska et al., 2006).

In addition, a and y synuclein proteins have also been found elevated in cerebral spinal
fluid (CSF) in elderly individuals with Alzheimer's disease, Lewy body disease, and
vascular dementia when compared to normal controls. y-synuclein had greater elevation

in CSF of patients with Lewy body disease. Elevated synuclein -a and y were found in
CSF of patients in Braak stage 111and onward and then remained stable until Braak stage

N (Mukaetova-Ladinska et al., 2008). Braak stages represent a system used to classify
Alzheimer patients' stage in the disease. They span from stage I-VI and represent the
level of impairment in the patient. Stage I representing no impairment and stage VI
representing severe decline

(http://www.alz.org/alzheimersTSdiseaseSeaSestagesSoff
alzheimersap). Since y-synuclein is
expressed in nervous tissue and found to be highly expressed in nervous tissue of patients

with neurodegenerative disease, its DNA sequence was screened to search for possible
polymorphism mutations linked with neurodegenerative diseases states, such as
Parkinson's disease and ALS. Polymorphisms have been reported but so far none of
them is found to be d i i t l y correlated with the disease state (Lincoln et al., 1999).

Presence of *y-synucleinin Cancers
Up to now, y-synuclein has been found in many different types of cancers, including
pancreatic adenocarcinoma, uterine papillary serous carcinoma, breast, colorectal,
ovarian, lung, liver, gastric cancer, and bladder cancer (Li et al., 2004, Huh et al., 2009,
Hibi et al., 2009, Morgan et al., 2009, Liu et al., 2007, Zhao et al., 2006, Yanagawa et al.,
2004 and Dokun et al., 2008). Its expression level is correlated to a number of facts
including cancer stage, lymph node involvement, metastasis, and penneural invasion.

For example, in a study using 93 breast carcinoma samples y-synuclein expression was
seen in 36% of all the samples, 81% of the samples from stage IIVIV, and 15% of the
samples in stage MI. Cancer stages depend on five factors, which include location of the
primary tumor, tumor size and number of tumors, lymph node involvement, cell type and
tumor grade, and the presence or absence of metastasis
(http://www.cancer.gov/cancertopics/factsheeetectiodstaging). No y-synuclein

expression was seen in normal breast tissue. It was also found that y-synuclein presence
in the primary tumor signified lymph node involvement and metastasis. Again, the
presence of y-synuclein in breast cancer patients had a significantly shorter disease free
survival and increased probability of death (Wu et al., 2007).

The trend of 7-synuclein expression and advanced stage cancer is also found in liver and
gastric cancer as well. In liver cancer samples y-synuclein was expressed in 67% of all
samples, 5.3% of stage I samples, 88% in stage IIIIIV samples, and 100% on metastasis
samples (Zhao et al., 2006). In gastric cancer samples y-synuclein was expressed 40% in
primary cancers, 51% in primary cancers with lymph node metastasis, 26% in gastric
cancer without lymph node involvement, 48% in stage 11-IV samples, and 27% in stage I.
y-synuclein was not expressed at all in benign tissue. These also suggest that there is a
higher y-synuclein expression in advanced cancer stages and metastasis phase (Yanagawa
et al., 2004).

Using a pancreatic cell line, proteomic and transcriptomic analyses confirmed that ysynuclein is the only upregdated protein found in p e ~ e u r ainvasion,
l
which is the
growth of tumor along nerve branching, providing a path for tumor invasion into new
tissue. The expression of y-synuclein was found correlated to perineural invasion and
lymph node metastasis, diminished overall survival, and the strongest negative indicator
of disease free survival. Knockdown y-synuclein expression significantly decreased
perineural invasion and liverllymph nodes metastasis (Hibi et al., 2009).

In conclusion, y-synuclein is highly expressed in the advanced cancer stages and not

expressed at all in normal tissue, except neuronal cells. Therefore, y-synuclein may be
used as a biological biomarker for these cancers.

Regulation of y-synuclein expression by DNA Methylation
When analyzing the promoter region of y-synuclein in cancer cell lines where it is
overexpressed, this region was found to be hypomethylated at CpG islands. Exogenous
overexpression of DNMT3B, a DNA methyl transferase, causes suppression of ysynuclein mRNA and protein expression in a lung cancer cell line. This caused induction
of de novo methylation of y-synuclein CpG island. When siRNA was used to knockdown DNMT3B there was an increase in y-synuclein expression. Carcinogens, such as
cigarette smoke extract (CSE), have been found to induce down regulation of DNMT3B
and lead to y-synuclein increased expression (Liu et al., 2007).

Similar results were also found in breast and ovarian cell lines, as well as using samples
f h m the patients' bladder, gastric, and liver samples (Gupta et al., 2003, Zhao et al., 2006,
Yanagawa et al., 2004 and Dokun et al., 2008). These data have given some insight on
how to tackle the problems that y-synuclein's expression causes. Since a proposed cancer
treatment was the use of 5-aza-2'deoxycytidiie to prevent the methylation of tumor
suppressor genes, it's now found to activate prometastatic genes, y-synuclein (Ateeq et al.,

2008). In conclusion, y-synuclein found in cell lines in which it is overexpressed is
correlated to a hypomethylated promoter region.

Rationale
From above, both PCBPl and y-synuclein have been reported to play various mles in the
cell. Up to now there is no report in the literatures showing the interaction of these two
proteins. Therefore, this study is to examine their physical interaction in vivo using
mammalian system, and explore the possible functional role of this interaction.

Materials and Methods

Cell Culture
T47D, H292, Mcf-7, HCTl16 and HT29 cell lines were obtained from ATCC. NMB (KO
et al., 2005), T47D, and H292 cell lines were maintained in Roswell Park Memorial
Institute Medium (RPMI). Mcf-7 cell line was maintained in Dulbecco's Modified
Medium (DMEM).HCTl16 and HT29 cell lines were maintained in McCoy's media
Ail medium were supplemented with 10% Fetal Calf Senun and all cell limes were
maintained at 37°C in a 5% COz incubator.

Lowry Assay

Using bovine serum albumin as a standard, protein concentrations were determined using
Lowry assay. Lysate samples were incubated at room temperature with solution C
(1.8mM Na2CO3,98mM NaOH, 0.95mM sodium potassium tartarate, and 0.4rnM CuS04
5Hz0) for 10 minutes and further incubated with IN Folim Ciocalteu's Phenol reagent for
30 minutes. The samples were examined at 660nm using colorimetry to determine the
protein concentration.

Western Blot Analysis

Samples were separated on a 12% sodium dodecyl sulfate-polyacrylamidegel
electrophoresis (SDS-PAGE) and then electrotransferredto phenylethylsulfonyl fluoride
(PVFD) membranes. AAer a series of washes in .l% and .3% TTBS (Tween-20 Tris

Buffered Saline), the membrane was probed with a specific antibody. The signals were
detected using an enhanced chemiluminesence detection system (Amersharn Biosciences).
The anti-PCBP1 and y-synuclein antibodies were purchased from Santa Cruz
Biotechnology.

Co-Immunoprecipitation

Cell lysate was first incubated with anti-PCBP1 antibody or negative control and then
added Protein G-agarose beads. The beads were washed with PBS and then the
immunocomplex was eluted using treatment buffer containing SDS.

RNA Isolation
RNA from cells were extracted using Tri-Reagent fmt and then with chloroform. The

mixture was subjected to centrifugation. The top phase containing total RNA was
removed. RNA was precipitated using isopropanol.

RT-PCR
F i t strand cDNA was synthesized using total RNA and the random primer, in the
presence of reverse transcriptase. Amplification was performed as 50 minutes at 37'C
and 15 minutes at 70°C. PCR amplification of cDNA was performed as 1 minute at 95'C,
35 seconds at 68"C, and 35 seconds at 72'C for 32 cycles. The y-synuclein primers were
as follows: upper, S'GTGGAGGAGGCGGAGAACATC :lower,

3'CCTCTAGTCTCCCCCACTCTG.

pCR2.1 Cloning
PCR product was cloned into with the cloning site of pCR2.1 vector, purchased from
Invitrogen . E. coli competent cells were then transformed with the ligation mixture
using the heat shocking method. The transformants were then selected using ampicillin
LB agar plates.

Small Scale Plasmid PuriTcation
Plasmids were extracted from cultures using Qiaprep Miniprep Kit from Qiagen.
Cultures were centrifuged and pellets were resuspended in P1 (50mM glucose, lOmM
EDTA, pH 8.5,25mM Tris HCI, pH 8). They were lysed using Lysis Buffer P2 (0.2M
NaOH, 1% SDS), and then neutralized by adding Neutralizing Buffer N3 (5M potassium
acetate, glacial acetic acid). The plasmids are separated by centrifugation and applied to
Qiaprep spin column, which was washed with Buffer PB and PE. The plasmids were
eluted by Buffer EB (1OmM Tris HCI, 1mM EDTA, pH 8.4).

Large %ale Plasmid Purification
Bacteria cultures were grown overnight at 37°C. The plasmids were extracted using
Qiagen Plasmid Maxiprep Kit from Qiagen. Bacteria cultures were centrifuged and the
pellet was resuspended in lOmL of Buffer Pl(50mM glucose, 1OmM EDTA, pH 8.5,
25mM Tris HCl, pH8). The bacteria suspension was then lysed by adding 10 mL of
Lysis Buffer P2 (0.2M NaOH, l%SDS), which were further neutralized by addiig 10 mL
of Neutralizing Buffer P3 (5M potassium acetate, glacial acetic acid). The mixture was

centrifuged at 15,000 rpm. The supernatant was loaded to a Qiagen-tip column, which
was then washed with Buffer QC. The plasmid was eluted using Buffer QF, and it was
precipitated using isopropanol precipitation method.

Transfection and Reporter Gene Assay
NMB cells were transfected using lipofection method with various concentrations of
plasmids containing pcDNA3?-synuclein, pcDNA3-SNP y-synuclein, or blank vector
(pcDNA3), individually. The pGL3 plasmid containing the luciferase reporter gene
driven by the human MOR promoter was also added in each sample. The pCHl10
plasmid was included as an internal standard. Twenty four hours after transfection, cells

are harvested and lysed. The luciferase activity was then measured using luciferase
reagent (Promega) with a iuminometer (Berthold).

Results

Vedication of different cell Lines expressing y-synuclein and PCBPl endogenously
The interaction between PCBPl and y-synuclein has been examined via in vivo validation
using the two-hybrid system as well as using the GST pull-down assay (lab unpublished
data). To further determine if this interaction also occurred in the mammalian system, the

human cell model system was selected. The literatures were. searched first. Based on
published data, a total of six cell lines were chosen, including neuroblastoma (NMB) (lab
data), lung cancer (H292) (Liu H et al., 2007), breast cancer (T47-D & Mcf-7) (Liu C et
al., 2008 and lab data), and colorectal cancer (HCT-116 62 HT29) (Liu C et al., 2008),
which were reported to express y-synuclein endogenously. Therefore, the endogenous
expression of both PCBPl and y-synuclein was examined first using Western blot
analysis with cell lysates &om these cells and anti-PCBP and anti-ysynuclein antibodies.
Although the monomer form of y-synuclein is 13kDa, it is reported to have a high
tendency to form aggregates (Sung et al., 2007). As in Fig. 1, Western blot analysis
showed the aggregated forms of y-synuclein observed in the different cell lines. In
Figure 2 results showed PCBPl expression in all mammalian cell lines.

Figure 1: Examination of y-synuclein expression using six cell lines.
Endogenous expression of y-synuclein was determined via Westem Blot analysis, using T47D,H292,
HT29,HCTl16, NMB and Mcf-7cell lysate and anti-y-synuclein antiidy. Arrows indicate the positions
of protein markers.

Mcf-7

NMB

Figure 2: Examination of PCBPl expression using six cell lines.
Endogenous expression of PCBPl was determined via Western Blot analysis, using T47D, H292,HT29,
HCTl16, Mcf-7, and MB cell lysate and anti-PCBP antibody. Arrows indicate the positions of protein
markers.

Determination of physical interndon using mammalian cell lines
To examine the PCBPl and y-synuclein interaction in the mammalian cell system, coimmunoprecipitation was performed using a PCBPl specific antibody. This technique
can be used to determine the protein-protein interaction, for if an endogenous proteinprotein interaction exists, then the PCBPl antibody will pull down PCBPl and its
interacting proteins. The immunoprecipitated complex will then be able to be examined
using SDS-PAGE and Western Blot analysis.

Cell lysate was incubated with anti-PCBPlantibody and without antibody separately as a
negative control, and then protein G agarose beads were added. The coimmunoprecipitants were subjected to SDS-PAGE and then Western Blot analysis. In
figure 3A, NMB cell lysate was used, and in figure 3B, H292 cell lysate was used. The
blots were probed with anti-synuclien antibody and re-probed with anti-PCBP1 antibody
to confirm the pull-down of PCBP protein. A y-synuclein band was seen showing it was

pulled down (shown in Figures 3A and 3B), and also a PCBPl band was seen showing
pull down occurred (data not shown). No bands were seen for cell lysates incubated with
no antibody. These results show that when PCBPl is pulled down, y-synuclein is pulled
down as well, suggesting that a physical interaction between PCBPl and y-synuclein is
taking place endogenously in these mammalian cell line. (Figure 3) Also, the negative
control results validate the co-irnrnunoprecipitationresults by showing that without
antibody no pull-down occurs.

-

This procedure was performed using 6 different cell lines, Mcf-7 and T47-D (breast
cancer cell lies), HT29 and HCTl16 (colorectal cancer cell lines), H292 (lung cancer
cell line) (Fig 3B), and NMB (neuroblastoma) (Fig 3A). The same pattern of proteinprotein interaction was observed in all cell lines.

Control C0.P

A.

3

9

Cootrol Co-IP

y-synwlein

m

B.

y-synuckin
38-

Figure 3: Co-Immunoprecipitation using mammalian cell lines
Figw A shows resulls using NMB mll lysalr: and Figw B shows resulls using HZ92 mll lywe. The
Western blot analysis was performed using y-synuclein antibody or without antibody. The band of ysynuclein appeared m both figures, showing that the PCBPl antibody pulled down y-synuclein with the
PCBP1. Lane 1 is the negative control. Lane 2 is the Co-IP using PCBPl antibody.

Examining the cDNA sequence of the 7-synuclein in mammalian cell Lines

To further confirm the existence of y-synuclein in these cell lines, the DNA sequences of
y-synuciein were examined using RT-PCR by using y-synuclein specific primers. The

RNA was isolated from NMB, H292, HT29,HCTl16, Mcf-7, and T47D cell lines. RTPCR was performed and the sizes of PCR products verified using electrophoretic analysis
(Figure 4). RT-PCR products were then cloned into pCR2.1 vector. Positive clones
containing the PCR products were screened by restriction enzyme digests followed by
electrophoretic analysis (Figure 5). The plasmids containing the PCR products were then
subjected for DNA sequencing. The DNA sequencing results showed a consistent
missense mutation at the C-terminal, when compared with GenBank's published cDNA
sequence. The mutation was a TIA mutation causing a valine residue to become a
glutamic acid residue

4OObps

Figure 4: Electrophoretic analysis of PCR products from HCT 116 cell

GAisolation 60m&ll

lysate was performed followed by RT-PCR to amplify the cDNA sequence by
using specific primers for ysynuclein. Agamm gel electrophoresis of the PCR product was performed to
verify. A band is seen at approximately 400bps corresponding to the 386bp 7-synuclein cDNA sequence.
Lane 1 is the lOObp ladder. Lanes 2-4 represent HCT116 cell lines endogenous cDNA amplified using RTPCR.

cell line
RT-PCR products w-& ligated with $R2.1 vector, hansfomed&d screened. To ensure positive clones
contained the y-synuclein insert, EcoRl digests followed by agarose gel electrophoresis was perfomed. An
insert band is indicated by arrow and a band is seen at a much higher size represen!ing the cut pCR2.1
vector. Lane 1 is the lOObp ladder. Lanes 2-4 represents HCT 116 cell l i e endogenous cDNA cloned into
pCR2.1 vector.

SNP of 7-synuclein

Multiple SNPs (single nucleotide polymorphisms) are available on NCBI's SNP database.
A database search was then performed for y-synuclein and a total of 53 SNPs were found

(Table l), including the missense mutation found expressed endogenously in the
mammalian cell lines. Below is a table listing the reference number and sequence of all
the SNPs found in the database for y-synuclein with the SNP matching the missense
mutation highlighted.

Table 1 :SNPs of y-synuclein
A total of 53 SNPs were found for y-synuclein in NCBI's SNP database. L i e 18 is the mutation matching
our sequence analysis.

Exploring the functional role of PCBPl and 7-synuclein interaction on the MOR
promoter activity

Since the above data showed that PCBPl and y-synuclein physically interacted
endogenously in the mammalian system, a possible functional role of this interaction can

be examined using the reporter gene assay. Since it is known that PCBPl can regulate
the expression of the mu-opioid receptor gene, this technique can therefore be used to
examine if y-synuclein has any effect on MOR promoter activity via its interacting with
PCBPl. Co-transfection was performed using .5, 1, and 2ug of pcDNA3-SNP or DB
plasmid or blank vector as a control, along with the luciferase reporter plasmid containing
the human MOR promoter. pcDNA3-SNP plasmid contains the DNA sequence of ysynuclein matching the SNP form and the pcDNA3-DB plasmid contains the DNA
sequence of y-synuclein matching the GenBank database fom. The reporter activity
using pcDNA3 blank vector is defined as 100%. The preliminary test (Figure 6) showed
the pcDNA3-SNP plasmid caused a slight expression increase at Sug and an expression
decrease to about 800! of the control when the concentration was increased, and the
pcDNA3-DB plasmid caused an expression increase at Sug and an expression decrease
to about 70% of the control when the concentration was increased. This shows that the
interaction between PCBPl and y-synuclein may affect MOR promoter expression;
however, more experiments need to be performed to further investigate.

Reporter Gene ,issiy
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( 5
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Figure 6: The effects of overexpressing SNP and DB forms of y-synuclein on the human
MOR promoter activities.
The black bars wpmsaits data ob&ined h m mnpks overcxpmwd with the DB form of ysynuclein. The
light grey bars represent the data obtained &om samples overexpressed with the SNP form of y-synuclein.
Tbe black and grey spotted bars represent the data obtained fromsamples overexpressed with blank vector.

Discussion
Protein-protein interactions affect many things inside the cell, including the change of a
protein's function. This concept has been reported for PCBPl, for it b i d s along with

hnRNP K and PCBP2 to c-myc mRNA causing positive translational effect (Evans et al.,
2003), while when it b i d s along with hnRNP A1 and hnRNP K to collagen mRNA it
causes mRNA stabilization (Thiele et al., 2004). In this present study one more PCBP
interacting protein, y-synuclein, was discovered by showing that y-synuclein and PCBPl
physically interact using six different mammalian cell lines found to endogenously
express both proteins via a literature search and Western Blot analysis. Coimmunoprecipitation followed by Western Blot analysis demonstrated this interaction.
When analyzing the Western Blot data obtained after co-immunoprecipitation, it is seen
that PCBPl only interacts with a form of y-synuclein approximately trimer in size,
approximately 39kDa.

The monomer protein of y-synuclein is 13kDa in size, but Western Blot analysis of
mammalian cell l i e lysate showed proteins of multiple sizes. There are possible reasons
for these results. First, this protein has a high propensity for aggregation (Sung et al.,
2007). The higher molecular weight protein expressed may be a multimer of the protein.

Second, the other possibility is that the higher molecular weight is due to post
translational modifications. Third, y-synuclein may be also interacting with another
protein and form a protein complex. y-synuclein has been proven to interact with PCBPl
in this study, but it has also been shown to act as a chaperone protein, biding along with

Hsp70 and Hsp90 to ER-a (estrogen receptor a) in the unliganded state in breast cancer.
This binding enhances the high affinity ligand-binding capacity of the receptor (Jiang et
al., 2004). Since it is know that y-synuclein interacts with multiple proteins, the higher
molecular weight seen may be due to a protein complex. Any of these possible
explanations for the higher molecular weight form seen can affect how the protein
interacts.

To M e r validate y-synuclein in these cell lies, its cDNA was analyzed and a
consistent missense mutation was found when compared with GenBank's published
cDNA sequence, which coded for a valine residue versus a glutamic acid residue. This
missense mutation was found in a SNP database search, with a total of 53 SNPs for ysynuclein. Since the synuclein family has been found to play a role in neurological
disorders, this mutation has been previously investigated using DNA screening and their
results indicates that this SNP (glutamic acid residue instead of valine residue) has no
direct correlation to the disease in Alzheimer's patients (Luedecking et al., 1999) and no
correlation was found for any known polymorphisms for Parkinson's disease or
amyotrophic lateral sclerosis (ALS) (Flowers et al., 1999). However, having a non-polar
residue versus a poladacidic residue, may affect the proteins 3D structure as well as
possible its biding activity.

To further investigate the role of PCBPl and y-synuclein's interaction, the luciferase
reporter gene assay was performed to see how their interaction may affect MOR

promoter activity via using both the database and SNP form of y-synuclein. Preliminary
data implicated that the interaction between y-synuclein and PCBPl may possibly affect

MOR promoter activity, and the database. form of y-synuclein may have a slight stronger
effect than the SNP form. However, this experiment needs to be repeated and confirmed.

PCBPl and y-synuclein have been shown to interact with each other as well as interact
with other proteins separately. It is a possibility that PCBPl and y-synuclein's interaction
with each other may display different functional role+) for each of them interacts with

the other protein@). For example, the interaction between PCBPl and y-synuclein may
affect y-synuclein's role as a chaperone protein in the biding to the unliganded state of
the ERa. Experiments would need to be performed to investigate this, such as coirnmunoprecipitation and confocal microscopy to see protein-protein interactions.

In conclusion, this study has identified a physical protein-protein interaction between
PCBPl and y-synuclein endogenously amongst six mammalian cell lines expressing both
proteins. To W e r investigate this interaction more functional assays, such as the
luciferase reporter gene assay need to be repeated. Also, immunofluresence followed by
confocal microscopy should be performed to further analyze the interaction as well as the
location inside the cell in which it takes place. Using truncated cloned forms of both
PCBPl and y-synuclein to screen to find the location on each protein in which this
interaction takes place should be performed to give more insight on how this interaction
works.
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